Form 4: Zoetis Inc. Director Sanjay Khosla Reports Stock Unit Transactions

Director Sanjay Khosla reports acquisition of deferred stock units and vesting of restricted stock units in Zoetis Inc.

Summary

• On February 8, 2025, Sanjay Khosla, a director of Zoetis Inc., reported transactions involving restricted stock units (RSUs) and deferred stock units (DSUs).
• The transactions include the vesting of 1,225.4023 RSUs, which were then converted into deferred stock units (DSUs) under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan.
• Khosla also acquired 1,225.4023 deferred stock units (DSUs) pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan.
• Following these transactions, Khosla beneficially owns 9,996.7233 deferred stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices and insider alignment with company performance. There are no indications of negative events or concerns.

Positives

• The vesting of restricted stock units and subsequent deferral into deferred stock units indicates a continued alignment of the director's interests with the long-term performance of Zoetis Inc.

Future Outlook

The deferred stock units will be settled in shares of Zoetis Inc. common stock upon the reporting person's separation from service as a director.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency into the holdings and transactions of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies like Zoetis, similar to filings made by directors and officers at companies like Pfizer (which spun off Zoetis) and Merck, both major players in the animal health industry.
• The use of restricted stock units and deferred compensation plans is a common method of executive compensation in the pharmaceutical and animal health industries, aligning executive interests with long-term shareholder value, similar to compensation structures at Elanco and Boehringer Ingelheim.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine compensation-related activities.
• The alignment of director interests with company performance through equity ownership can be viewed positively by shareholders.

Key Dates